Atorvastatin-Induced Diaphragmatic Muscle Impairment-Reference-Cited by-同舟云学术

Atorvastatin-Induced Diaphragmatic Muscle Impairment

Published:2001-10 Issue:10 Volume:35 Page:1292-1293
ISSN:1060-0280
Container-title:Annals of Pharmacotherapy
language:en
Short-container-title:Ann Pharmacother

Author:

Sulem Patrick¹,Bagheri Haleh²,Faixo Yves³,Montastruc Jean Louis⁴

Affiliation:

1. Resident Service de Pharmacologie Clinique Centre Midi-Pyrénées de Pharmacovigilance de Pharmacoépidémiologie et d'Informations sur le Médicament Faculté de Médecine Hôpitaux de Toulouse Toulouse, France

2. Hospital Practitioner Service de Pharmacologie Clinique Centre Midi-Pyrénées de Pharmacovigilance de Pharmacoépidémiologie et d'Informations sur le Médicament Faculté de Médecine Hôpitaux de Toulouse 37 Allée Jules Guesde 31073 Toulouse Cedex, France FAX 33561255116

3. General Practitioner Flourens, France

4. Head of Department Service de Pharmacologie Clinique Centre Midi-Pyrénées de Pharmacovigilance de Pharmacoépidémiologie et d'Informations sur le Médicament Faculté de Médecine Hôpitaux de Toulouse

Publisher

SAGE Publications

Subject

Pharmacology (medical)

Link

http://journals.sagepub.com/doi/pdf/10.1345/aph.10366

Reference5 articles.

1. HMG-CoA Reductase Inhibitors and Myotoxicity

2. A method for estimating the probability of adverse drug reactions

3. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel investigation of statins myotoxic mechanism: effect of atorvastatin on respiratory muscles in hypoxic environment;Toxicology Letters;2019-05

2. Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement;International Journal of Cardiology;2016-12

3. HMG coenzyme-A reductase inhibitors;Meyler's Side Effects of Drugs;2016

4. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel;Expert Opinion on Drug Safety;2015-04-24

5. Neuropsychiatric Adverse Events Associated with Statins: Epidemiology, Pathophysiology, Prevention and Management;CNS Drugs;2014-01-17